Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (cosopt) on monotherapy with latanoprost (xalatan) in patients with elevated intraocular pressure: A prospective, 4-week, open-label, randomized, controlled clinical trial

Journal of Glaucoma

Volumn 19, Issue 5, 2010, Pages 331-335

  Hatanaka, Marcelo ^a   Reis, Alexandre ^a   Sano, Milena Eimi ^a   Susanna, Remo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Clinical management; Diurnal tension curve; Dorzolamide; Fixed combinations; Latanoprost; Ocular hypertension; Open angle glaucoma; Timolol; Water drinking test

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; PROSTAGLANDIN F; SULFONAMIDE; THIOPHENE DERIVATIVE; TIMOLOL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; WATER LOADING; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; TIME; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIME FACTORS; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77953975084     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181b4cab4     Document Type: Article

References (29)

1. Fechtner RD, McCarroll KA, Lines CR, et al. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther. 2005; 21:242-249.
2. Konstas AG, Kozobolis VP, Tsironi S, et al. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology. 2008;115:99-103.
3. Rismanchian A, Eslami F, Moieni H, et al. Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma. Saudi Med J. 2008;29:384-387.
4. Miller D. The relationship between diurnal tension variation and the water-drinking test. Am J Ophthalmol. 1964;58: 243-247.
5. Frankelson EN. The role of the water test in evaluation of glaucoma control. Can J Ophthalmol. 1974;9:408-410.
6. Helal J. Contribuição ao estudo da pressão intra-ocular: picos de pressão intra-ocular na curva diá ria de pressão e na prova de sobrecarga h?́drica. Rev Bras Oftalmol. 1988;47:75-80.
7. Vasconcelos-Moraes G, Susanna R Jr. Correlation between the water drinking test and modified diurnal tension curve in untreated glaucomatous eyes. Clinics. 2008;63:433-436.
8. Susanna R, Medeiros FA, Vessani RM. Correlation between intraocular pressure peaks in the diurnal tension curve and in the water-drinking test (ARVO Abstract). Invest Ophthalmol Vis Sci. 2001;42:S558 (abstract no. 2995).
9. Medeiros FA, Leite CA, Notrispe CR, et al. Correlação entre os picos pressó ricos da curva tensional diá ria e do teste de sobrecarga h?́drica. Estudo em pacientes com glaucoma primá rio de â ngulo aberto em uso de tilmolol e dorzolamida. Rev Bras Oftalmol. 2001;5:21-23.
10. Susanna R Jr, She WP, for the Latin American Glaucoma Society. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther. 2004;26:755-768.
11. Vetrugno M, Sisto D, Trabucco T, et al. Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications. J Ocul Pharmacol Ther. 2005; 21:250-257.
12. Susanna R Jr, Hatanaka M, Vessani RM, et al. Correlation of asymmetric glaucomatous visual field damage and water-drinking test response. Invest Ophthalmol Vis Sci. 2006;47:641-644.
13. Susanna R Jr, Vessani RM, Sakata L, et al. The relation between intraocular pressure peak in the water drinking test and visual field progression in glaucoma. Br J Ophthalmol. 2005;89:1298-1301.
14. Malerbi FK, Hatanaka M, Vessani RM, et al. Intraocular pressure variability in patients who reached target intraocular pressure. Br J Ophthalmol. 2005;89:540-542.
15. Zhang W, Po A, Dua H, et al. Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001;85:983-990.
16. Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology. 1996;103: 1916-1924.
17. Lesk MR, Koulis T, Sampalis F, et al. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother. 2008;42:498-504.
18. Kidd MN, O'Conner M. Progression of field loss after trabeculectomy: a five-year follow-up. Br J Ophthalmol. 1985;69: 827-831.
19. Schulzer M, Mikelberg FS, Drance SM. Some observations on the relation between intraocular pressure and the progression of glaucomatous visual field loss. Br J Ophthalmol. 1987;71: 486-488.
20. O'Brien C, Schwartz B, Takamoto T, et al. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol. 1991;111:491-500.
21. Chauhan BC, Drance SM. The relationship between intraocular pressure and visual field progression in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1992;230:521-526.
22. Drance SM. Diurnal variation of intraocular pressure in treated glaucoma. Arch Ophthalmol. 1963;70:302-311.
23. Zeimer RC, Wilensky JT, Gieser DR, et al. Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology. 1991;98:64-69.
24. Katavisto M. The diurnal variations of ocular tension in glaucoma. Acta Ophthalmol. 1964;78(suppl):1-131.
25. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.
26. Yoshikawa K, Inohue T, Inohue Y. Normal tension glaucoma: the value of predictive tests. Acta Ophthalmol. 1993;71:463-470.
27. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the Collaborative Glaucoma Study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol. 1980;98:2163-2171.
28. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al, Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627-1635.
29. Leske MC, Heijl A, Hussein M, et al, Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56. (Pubitemid 36401765)